Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC): 2nd Spanish Lung Cancer Group (GECP) expert consensus statement
Por:
Ospina-Serrano, AV, González-Larriba, JL, Nadal, E, Trancho, FH, Bosch-Barrera, J, Calvo, V, Bolufer-Nadal, S, de la Cruz, JLCC, Macía-Vidueira, I, Alvarez-Kindelán, A, Del Barco-Morillo, E, Bernabé-Caro, R, Casal-Rubio, J, Cilleruelo-Ramos, A, Cobo-Dols, M, Dómine-Gómez, M, Figueroa-Almánzar, S, Insa-Mollá, A, Jarabo-Sarceda, JR, Jiménez-Maestre, U, López-Castro, R, Majem, M, Martinez-Marti, A, Téllez, EM, Sánchez-Lorente, D, López-Valcárcel, M, Couñago, F, Garcia-Campelo, R, de Castro, J, Massuti-Sureda, B, Provencio, M
Publicada:
30 sep 2025
Resumen:
Background: In light of the ongoing advancements in the treatment of patients with early- and locally advanced-stage non-small cell lung cancer (NSCLC), the members of the Spanish Lung Cancer Group (GECP) deemed it necessary to update its 2023 consensus suggestions for the management of these patients. Methods: From July to November 2024, a panel of experts, including thoracic surgeons, radiation oncologists, and medical oncologists, was convened. The consensus process was developed using a mixed approach that incorporated Delphi and nominal group techniques. The consensus coordination group reviewed the relevant scientific literature for the update and developed a questionnaire for the panel of experts to vote on. Two rounds of voting were conducted, followed by a final nominal group meeting to discuss clinical situations where consensus had not been reached and draw final conclusions. In instances where high-quality scientific data were not available or were the subject of controversy, final suggestions were based on the expertise of the participants. Results: Thirty experts from the multidisciplinary team participated in the voting and discussions. The document was updated to incorporate recent advancements in molecular diagnosis and biomarkers, the role of the multidisciplinary thoracic committee, criteria for neoadjuvant/perioperative treatment, approaches to inoperable/unresectable disease, and adjuvant treatment. Proposals that did not require updating were not voted on again and remain part of the document, maintaining their first version. Conclusions: Updated suggestions were developed for the most relevant situations in the treatment of patients with early-stage and locally advanced NSCLC. These suggestions will support clinical decisionmaking in daily practice. This paper presents the statements developed by the expert panel and summarizes the scientific evidence supporting them.
Filiaciones:
Ospina-Serrano, AV:
Puerta de Hierro Majadahonda Univ Hosp, Dept Med Oncol, Joaquin Rodrigo 1 St, Madrid 28222, Spain
González-Larriba, JL:
Univ Complutense Madrid, Hosp Clin San Carlos, Dept Med Oncol, Madrid, Spain
Nadal, E:
Bellvitge Biomed Res Inst IDIBELL, Catalan Inst Oncol ICO, Dept Med Oncol, Bellvitge Healthcare Campus, Lhospitalet De Llobregat, Barcelona, Spain
Trancho, FH:
San Carlos Clin Hosp, Dept Thorac Surg, Madrid, Spain
Bosch-Barrera, J:
Hosp Univ Dr Josep Trueta, Inst Catala Oncol, Dept Med Oncol, Girona, Spain
Inst Invest Biomed Girona IDIBGI CERCA, Precis Oncol Grp OncoGIR Pro, Girona, Spain
Calvo, V:
Puerta de Hierro Majadahonda Univ Hosp, Dept Med Oncol, Joaquin Rodrigo 1 St, Madrid 28222, Spain
Bolufer-Nadal, S:
Dr Balmis de Alicante Univ Hosp, Dept Thorac Surg, Alicante, Spain
de la Cruz, JLCC:
12 Octubre Univ Hosp, Dept Thorac Surg, Madrid, Spain
Macía-Vidueira, I:
Bellvitge Univ Hosp, Dept Thorac Surg, Barcelona, Spain
Alvarez-Kindelán, A:
Reina Sofia Univ Hosp, Dept Thorac Surg, Cordoba, Spain
Del Barco-Morillo, E:
Complejo Asistencial Univ Salamanca, IBSAL, Salamanca, Spain
Bernabé-Caro, R:
Virgen del Rocio Univ Hosp, Dept Med Oncol, Seville, Spain
Casal-Rubio, J:
Alvaro Cunqueiro Univ Hosp, Dept Med Oncol, Vigo, Spain
Cilleruelo-Ramos, A:
H Clin Univ Valladolid, Dept Thorac Surg, Valladolid, Spain
Cobo-Dols, M:
Malaga Reg Hosp, Dept Med Oncol, Malaga, Spain
Dómine-Gómez, M:
Fdn Jimenez Diaz Univ Hosp, Dept Med Oncol, Madrid, Spain
Figueroa-Almánzar, S:
Valencia Univ Clin Hosp, Dept Thorac Surg, Valencia, Spain
Insa-Mollá, A:
Valencia Univ Clin Hosp, Dept Med Oncol, Valencia, Spain
Jarabo-Sarceda, JR:
San Carlos Clin Hosp, Dept Thorac Surg, Madrid, Spain
Jiménez-Maestre, U:
Cruces Univ Hosp Barakaldo, Dept Thorac Surg, Bizkaia, Spain
López-Castro, R:
Valladolid Univ Hosp, Dept Med Oncol, Valladolid, Spain
Majem, M:
De La Santa Creu & St Pau Hosp, Dept Med Oncol, Barcelona, Spain
Martinez-Marti, A:
Vall Dhebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
Téllez, EM:
Hosp Santa Creu & Sant Pau, Dept Thorac Surg, Campus Salut Barcelona, Barcelona, Spain
Res Inst St Pau, TRAIL Sci Res Grp, Barcelona, Spain
Sánchez-Lorente, D:
Parc Tauli de Sabadell Univ Hosp, Dept Thorac Surg, Barcelona, Spain
López-Valcárcel, M:
Puerta de Hierro Majadahonda Univ Hosp, Dept Radiat Oncol, Madrid, Spain
Couñago, F:
European Univ Madrid, Fac Med Hlth & Sports, Dept Med, Madrid, Spain
San Francisco Asis & La Milagrosa Hosp, Dept Radiat Oncol, GenesisCare, Madrid, Spain
Garcia-Campelo, R:
A Coruna Univ Hosp, Dept Med Oncol, La Coruna, Spain
de Castro, J:
La Paz Univ Hosp, Dept Med Oncol, Madrid, Spain
Massuti-Sureda, B:
Dr Balmis Alicante Univ Hosp, Dept Med Oncol, Alicante, Spain
Provencio, M:
Puerta de Hierro Majadahonda Univ Hosp, Dept Med Oncol, Joaquin Rodrigo 1 St, Madrid 28222, Spain
Green Submitted, gold
|